Open AccessToxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab
Author(s) -
Allison Y. Ye,
John Hay,
Janessa Laskin,
Jonn Wu,
Cheryl Ho
Publication year - 2013
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.126455
Subject(s) - medicine , cetuximab , mucositis , head and neck squamous cell carcinoma , rash , oncology , nausea , radiation therapy , toxicity , univariate analysis , head and neck cancer , multivariate analysis , cancer , colorectal cancer
The standard of care for locally advanced head and neck squamous cell carcinoma (HNSCC) is radiation therapy (RT) with concurrent cisplatin (CIS). Patients with renal or cardiac dysfunction, hearing loss or poor performance status (PS) may receive RT and cetuximab (CET) at our institution. This study compares treatment toxicities and outcomes.